Find support groups, events and resources near you

ZERO Summit 2021 banner

BiTE Technology in Immuno-Oncology

Graphic about BiTE technology

Doctor Michael Groaning of Amgen discusses a new, groundbreaking immuno-oncology platform - Bispecific T-cell engager technology, or BiTE.

This session was part of our VIRTUAL ZERO Prostate Cancer Summit, a free online event that took place from February 28 to March 4, 2021.


Watch

Contributors

Michael Groaning PHD Headshot
Michael Groaning, PhD, Prostate Cancer Global Medical Affairs Lead

Dr. Groaning attended Colorado State University until 2000 when he moved to Zurich, Switzerland for his post-doctoral studies at the Swiss Federal Institute of Technology (ETH). Dr. Groaning started his career in the pharmaceutical industry at F. Hoffmann – La Roche in Basel, Switzerland in their Discovery Chemistry group before transferring to Boulder, Colorado as a process research chemist where he optimized the production of a key intermediate for Tamiflu.

Share